Effect of Meal Timing During Adjuvant Treatment for Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT07524218
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Time-restricted eating — BEHAVIORAL
    Participate in time-restricted eating plan
  • Questionnaire Administration — OTHER
    Complete questionnaire
  • Biospecimen Collection — PROCEDURE
    Undergo collection of blood and stool
  • Health coaching — BEHAVIORAL
    Receive nutrition counseling

Study Details

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response, patient well-being and long-term metabolic health. In alignment with these priorities, we propose to focus on patients with histologically or cytologically confirmed solid tumors treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and/or radiation per standard of care). A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.

Key Dates

Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
Aug 31, 2029
Completion
Aug 31, 2029

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Time-restricted eating (TRE)
    Participants assigned to the TRE group will have an 8-hour daily eating period, starting 1-3 hours after waking up \[8 hours eating / 16 hours fasting per day (6+ days a week)\].
  • Active Comparator: Control group
    Participants assigned to the control group are not time-restricted, and have a 12+ hour window of eating per day.

Primary Outcome Measure

Patient-reported treatment-related toxicities: Average weekly scores [ Time Frame: Assessed weekly from start of intervention through end of intervention (up to approximately 6 months) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars Sinai Medical Center (CSMC)Los AngelesCalifornia90048
Jane Figueiredo
[email protected]
(310) 423-2746
Jane Figueiredo, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
Cedars Sinai Medical Center (CSMC)· Los Angeles, CA

Related Studies